SCHEMBL6033433

SCHEMBL6033433

[c]1ccnc(CN2CCOCC2)n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.45
HRH3 Q9Y5N1 2/20 0.40
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
CYP2A13 Q16696 5/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6270109 0.78 CXCR4 (0.53) CXCR4HRH3HSD17B10ALDH1A1CYP2C9
SCHEMBL5597102 0.73 KDM1A (0.41) MEN1KMT2AKDM4EHTT
SCHEMBL5596338 0.73 HRH3 (0.48) HRH3ALDH1A1KMT2AHTTSMN1; SMN2
SCHEMBL5801843 0.72 CYP1A2 (0.43) ALDH1A1CYP2C9KDM4E
SCHEMBL1750786 0.71 MKNK1 (0.49) HSD17B10ALDH1A1CYP2C9MEN1KMT2A
SCHEMBL1110443 0.70 POLB (0.41) HSD17B10ALDH1A1KMT2AHPGDKDM4E
SCHEMBL7831897 0.70 CXCR4 (0.49) CXCR4HRH3HSD17B10ALDH1A1CYP2C9
SCHEMBL5596422 0.69 CDK4 (0.47) ALDH1A1KMT2AKDM4EGLAGAA
SCHEMBL3512357 0.69 CXCR4 (0.47) CXCR4HRH3HSD17B10ALDH1A1CYP2C9
SCHEMBL465756 0.69 CXCR4 (0.47) CXCR4HRH3HSD17B10ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 CXCR4 381/4885HRH3 108/4885HSD17B10 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.